Newsmeme!
Discover News you didn't know existed
Peptide
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Hope for Alzheimer`s patients? Dipeptide blocks the formation of toxic amyloid β-peptide aggregates in mice
Published December 4, 2008, 9:41 am, PhysOrg
(PhysOrg.com) -- Alzheimer's disease is the primary cause of age-related dementia. About 15 million people are affected by this neurodegenerative disease worldwide. It has so far not been possible to combat the causes of Alzheimer`s disease. Israeli researchers have now developed a novel approach for treatment. As they report in the journal Angewandte Chemie, the new drug, a molecule made from ...
ConjuChem's PC-DAC(TM):Exendin-4 Lowers Glucose And Weight In Phase II Diabetes Trials
Published December 4, 2008, 7:13 am, Medical News Today
ConjuChem Biotechnologies, Inc. (TSX:CJB) announced preliminary results today showing that its Type 2 diabetes product, PC-DAC(TM):Exendin-4, achieved statistically significant reductions in HbA1c and weight in its two Phase II clinical trials.
Ambrilia Biopharma and ZBx Corporation Enter Into an Exclusive License Option Agreement for the Worldwide Rights to ...
Published December 4, 2008, 6:20 am, CCNMatthews via Yahoo! Finance
MONTREAL, QUEBEC-- - Ambrilia Biopharma Inc. announced today that it has entered into an exclusive license option agreement with ZBx Corporation granting ZBx the worldwide rights to develop, manufacture and commercialize Ambrilia's PSP94 technology in ZBx's Zap Rapid Test Systems and Assays.
Anavex presents potent neuroprotective effects of Anavex 1-41 at Neuroscience 2008
Published December 4, 2008, 6:00 am, PR Newswire via Yahoo! Finance
Anavex Life Sciences Corp. , a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System diseases and cancer, was selected to present its latest results with ANAVEX 1-41 at Neuroscience 2008, the 38th annual meeting of the Society for Neuroscience, which took place November 15-19, 2008 in Washington, DC.
New Protocol and Products for Anti-Aging and Skincare Professionals Announced
Published December 4, 2008, 5:21 am, PR.com
TBI, Inc. has announced protocol in cooperation with a new genetically engineered human protein that replaces up to two years of lost elastin in the first treatment. The 45 minute treatment uses TBI’s Chiro950™ or BI Model 900 Microcurrent units and professional grade Dermalastyl®. [PR.com - December 04, 2008]
Latest Research Into A Vaccine For Coeliac Disease Announced At Conference
Published December 4, 2008, 5:13 am, Medical News Today
Coeliac UK, the national charity for people with coeliac disease, is hosting a conference on Wednesday 3rd December at the Royal Society of Arts in central London announcing the latest findings in coeliac disease research including progress on the development of a possible vaccine for the condition.
Data on Stapled Peptide Drugs to Be Presented at ASH Annual Meeting
Published December 4, 2008, 5:00 am, Business Wire via Yahoo! Finance
CAMBRIDGE, Mass.----Aileron Therapeutics announced today that investigators from Aileron and the Dana-Farber Cancer Institute will present data from multiple preclinical studies on stapled peptide drug candidates at the 50th Annual Meeting of the American Society of Hematology in San Francisco, Calif., December 6 to 9, 2008.
BioSET Announces Initiation Of Clinical Trials For AMPLEX Osteo-Promotive Bone Graft System For Spine Fusion
Published December 4, 2008, 12:53 am, BioresearchOnline
BioSurface Engineering Technologies, Inc. [BioSET], a privately held company developing synthetic peptide growth factor mimetics for advanced tissue repair, reported recently that two pilot clinical trials, one in the United States and one in Canada, have been initiated with the Company's AMPLEX osteo-promotive bone graft system.
BioSeek Licenses Two Novel Anti-Inflammatory Peptides
Published December 3, 2008, 10:04 pm, DrugDiscoveryOnline
BioSeek, Inc., a pioneer in the application of predictive human biology to drug discovery, announced today that it has exclusively licensed two novel anti-inflammatory peptides from Amylin Pharmaceuticals, Inc. The two novel peptides were identified as candidates for development by BioSeek as a result of an ongoing joint research collaboration initiated between the two companies in 2007. These ...
ConjuChem's PC-DAC(TM):Exendin-4 Lowers Glucose and Weight in Phase II Diabetes Trials
Published December 3, 2008, 2:52 pm, PR Newswire via Yahoo! Finance
ConjuChem Biotechnologies, Inc. announced preliminary results
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |